Compatibility of treprostinil sodium and dopamine hydrochloride during simulated Y-site administration

Am J Health Syst Pharm. 2020 Apr 1;77(8):649-657. doi: 10.1093/ajhp/zxaa025.

Abstract

Purpose: To evaluate the physical and chemical compatibilities of treprostinil sodium and dopamine hydrochloride.

Methods: Treprostinil sodium (4,000, 76,000, and 500,000 ng/mL) were mixed with dopamine hydrochloride (0.6, 3.2, 6, and 40 mg/mL). Samples were obtained at hours 0, 1, 2, and 4 for physical compatibility and chemical stability testing. Physical compatibility was assessed by visual examination and measurements of turbidity and pH. Drug concentrations were assessed using stability-indicating liquid chromatography mass spectrophotometry (LCMS) for treprostinil sodium and stability-indicating high-performance liquid chromatography (HPLC) for dopamine hydrochloride.

Results: Treprostinil sodium 4,000 and 76,000 ng/mL, when mixed with dopamine hydrochloride 0.6, 3.2, 6, and 40 mg/mL, were stable for 4 hours. Treprostinil sodium 500,000 ng/mL was stable when mixed with dopamine hydrochloride 0.6 mg/mL for 4 hours, but when mixed with dopamine hydrochloride 3.2, 6, and 40 mg/mL, significant precipitation was seen.

Conclusion: Treprostinil sodium 4,000 and 76,000 ng/mL were stable for 4 hours during simulated Y-site coadministration with dopamine hydrochloride 0.6, 3.2, 6, and 40 mg/mL. Treprostinil sodium 500,000 ng/mL is stable when mixed with dopamine hydrochloride 0.6 mg/mL.

Keywords: Y-site; administration; dopamine hydrochloride; i.v. compatibility; treprostinil sodium.

MeSH terms

  • Administration, Intravenous
  • Antihypertensive Agents / chemistry*
  • Dopamine / chemistry*
  • Dopamine Agents / chemistry*
  • Drug Incompatibility*
  • Epoprostenol / analogs & derivatives*
  • Epoprostenol / chemistry
  • Hydrogen-Ion Concentration
  • Time Factors

Substances

  • Antihypertensive Agents
  • Dopamine Agents
  • Epoprostenol
  • treprostinil
  • Dopamine